Regeneron and Intellia enter six-year CRISPR/Cas9 agreement; deal expanded
Under a six-year agreement, Regeneron Pharmaceuticals Inc. and Intellia Therapeutics Inc. will work together to advance Intellia's CRISPR/Cas9 gene editing technology for in vivo therapeutic use.
- Drug Delivery
- Gene Therapy, Cell Therapy
- Large Molecule
Drug Discovery Technologies
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.